SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS

Japanese Patent JP2014196363

A

PROBLEM TO BE SOLVED: To provide sphingosine-1-phosphate receptor antagonists.SOLUTION: There is increasing evidence for cross-talk between S1P1R and other growth factor receptors such as PDGFR. Thus, S1P1R receptor antagonists have the potential to offer clinical benefit as anti-cancer therapeutics. This disclosure relates to sphingosine-1-phosphate (S1P) receptor antagonists, compositions comprising the S1P receptor antagonists and methods for using and processes for making the S1P receptor antagonists. Especially this disclosure relates to sphingosine-1-phosphate 1 (S1P1) receptor antagonists, compositions comprising the S1P1 receptor antagonists, methods for using the S1P1 receptor antagonists to treat cancers, and processes for making the S1P receptor antagonists.

MOHAMED ABDULKADER IBRAHIM
JEONG JOON WON
HENRY WILLIAM BEECROFT JOHNSON
PATRICK KEARNEY
JAMES W LEAHY
GARY L LEWIS
ROBIN TAMMY NOGUCHI
NUSS JOHN M

JP2014148505A

October 16, 2014

July 22, 2014

Click for automatic bibliography generation  

EXELIXIS INC

C07D207/06; A61K31/167; A61K31/222; A61K31/277; A61K31/341; A61K31/343; A61K31/36; A61K31/381; A61K31/40; A61K31/4015; A61K31/4025; A61K31/4035; A61K31/404; A61K31/41; A61K31/4164; A61K31/4166; A61K31/4184; A61K31/4192; A61K31/4196; A61K31/42; A61K31/422; A61K31/427; A61K31/437; A61K31/438; A61K31/44; A61K31/4402; A61K31/4406; A61K31/4439; A61K31/454; A61K31/47; A61K31/4725; A61K31/495; A61K31/496; A61K31/4965; A61K31/498; A61K31/502; A61K31/505; A61K31/506; A61K31/5377; A61K31/54; A61K31/541; A61K31/55; A61P35/00; A61P35/02; A61P43/00; C07C231/14; C07C237/22; C07D207/08; C07D207/14; C07D207/16; C07D207/20; C07D207/277; C07D207/327; C07D207/452; C07D209/08; C07D209/14; C07D209/24; C07D209/42; C07D209/44; C07D209/48; C07D211/14; C07D211/58; C07D211/60; C07D211/62; C07D213/56; C07D213/74; C07D213/81; C07D213/82; C07D215/06; C07D215/48; C07D215/50; C07D215/54; C07D217/04; C07D233/61; C07D233/64; C07D233/78; C07D235/08; C07D237/28; C07D239/26; C07D239/42; C07D241/12; C07D241/44; C07D249/04; C07D249/08; C07D257/04; C07D261/08; C07D261/14; C07D263/32; C07D265/30; C07D277/04; C07D277/20; C07D277/54; C07D295/10; C07D295/18; C07D307/14; C07D307/24; C07D307/54; C07D307/68; C07D307/84; C07D317/60; C07D333/22; C07D333/24; C07D333/38; C07D333/70; C07D401/04; C07D401/06; C07D401/12; C07D403/06; C07D403/12; C07D403/14; C07D405/06; C07D409/06; C07D409/14; C07D413/06; C07D417/06; C07D417/12; C07D491/113

Shusaku Yamamoto
Natsuki Morishita

Previous Patent: LIQUID VACCINES FOR MULTIPLE MENINGOCOCCAL SEROGROUPS

Next Patent: PROTEASOME INHIBITOR